Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Roosmarijn Lurvink"'
Autor:
Thomas Blom, Roosmarijn Lurvink, Leonie Aleven, Maarten Mensink, Tom Wolfs, Miranda Dierselhuis, Natasha van Eijkelenburg, Kathelijne Kraal, Max van Noesel, Martine van Grotel, Godelieve Tytgat
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-re
Externí odkaz:
https://doaj.org/article/9b981075dae247d39e11d9760ced0861
Autor:
Miranda P Dierselhuis, Tom F.W. Wolfs, Natasha K. A. van Eijkelenburg, Leonie Aleven, Max M. van Noesel, Thomas Blom, Kathelijne C. J. M. Kraal, Martine van Grotel, Maarten Mensink, Roosmarijn Lurvink, Godelieve A.M. Tytgat
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2021)
Frontiers in Oncology, Vol 10 (2021)
The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b03e108eced597f7c7898c3e51c70c38
http://europepmc.org/articles/PMC7925836
http://europepmc.org/articles/PMC7925836